General Electric

About: General Electric is a company organization based out in Boston, Massachusetts, United States. It is known for research contribution in the topics: Turbine & Signal. The organization has 76365 authors who have published 110557 publications receiving 1885108 citations. The organization is also known as: General Electric Company & GE.

Equivalent Circuits-I

Abstract: Equivalent circuits have been found valuable in the solution of certain problems in that they simplify the analysis. Furthermore, equivalent circuits provide a means of replacing magnetic coupling with simple impedance links thereby permitting the use of the calculating board for solution. In Part I of this paper, the general equivalent mesh for the n-winding transformer is derived, and other less rigorous transformer circuits are discussed and compared. In Part II the mesh equivalent for the general network having (m + l) points of entry is derived and its application is explained. The generalizations of Parts I and II provide a background for the particular problem treated in Part III in which the study of system networks involving groups of parallel transmission lines is considered. The usually difficult problem of accurately determining ground fault currents in such a system is readily solved by applying the special equivalent circuits developed in Part III to a calculating board set-up of the system. These circuits are particularly valuable in the solution of any problem involving an analysis of the zero phase impedance diagram of a system. The methods and circuits developed in this paper are perfectly general and have many evident applications other than those treated.

Real-time interactive MRI on a conventional scanner.

Abstract: A real-time interactive MRI system capable of localizing coronary arteries and imaging arrhythmic hearts in real-time is described. Non-2DFT acquisition strategies such as spiral-interleaf, spiral-ring, and circular echo-planar imaging provide short scan times on a conventional scanner. Real-time gridding reconstruction at 8-20 images/s is achieved by distributing the reconstruction on general-purpose UNIX workstations. An X-windows application provides interactive control. A six-interleaf spiral sequence is used for cardiac imaging and can acquire six images/s. A sliding window reconstruction achieves display rates of 16-20 images/s. This allows cardiac images to be acquired in real-time, with minimal motion and flow artifacts, and without breath holding or cardiac gating. Abdominal images are acquired at over 2.5 images/s with spiral-ring or circular echo-planar sequences. Reconstruction rates are 8-10 images/s. Rapid localization in the abdomen is demonstrated with the spiral-ring acquisition, whereas peristaltic motion in the small bowel is well visualized using the circular echo-planar sequence.

Data object access system and method using dedicated task object

Abstract: A task management system for providing a graphically displayable worklist having one or more rows of work items, one or more of the work items each representing one or more data rows to be worked from one or more application data tables that are not a task object table of the task management system, the task management system comprising a task database having at least one task object, a first dedicated task object in said task database, said first dedicated task object having a second metadata associated therewith for graphically displaying information related to said first dedicated task object, a first view object having a first set of instructions for determining a first plurality of data rows of the one or more application data tables and a second set of instructions for creating a first association between each data row of said first plurality of data rows and said first dedicated task object, and a display generator for using said second metadata in initiating generation of display data representing a display image presenting a worklist, said worklist having a first one or more rows of application data table work items, each of said first one or more rows of application data table work items representing at least one data row of said first plurality of data rows.

Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice

Abstract: Loss of NF-E2-related factor 2 (Nrf2) signaling increases susceptibility to acute toxicity, inflammation and carcinogenesis in mice due to the inability to mount adaptive responses. In contrast, disruption of Keap1 (a cytoplasmic modifier of Nrf2 turnover) protects against these stresses in mice, although inactivating mutations in Keap1 have been identified recently in some human cancers. Global characterization of Nrf2 activation is important to exploit this pathway for chemoprevention in healthy, yet at-risk individuals and also to elucidate the consequences of hijacking the pathway in Keap1-mutant human cancers. Liver-targeted conditional Keap1-null, Albumin-Cre:Keap1(flox/−) (CKO) mice provide a model of genetic activation of Nrf2 signaling. By coupling global gene expression analysis of CKO mice with analysis of pharmacologic activation using the synthetic oleanane triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole (CDDO-Im), we are able to gain insight into pathways affected by Nrf2 activation. CDDO-Im is an extremely potent activator of Nrf2 signaling. CKO mice were used to identify genes modulated by genetic activation of Nrf2 signaling. The CKO response was compared with hepatic global gene expression changes in wild-type mice treated with CDDO-Im at a maximal Nrf2 activating dose. The results show that genetic and pharmacologic activation of Nrf2 signaling modulates pathways beyond detoxication and cytoprotection, with the largest cluster of genes associated with lipid metabolism. Genetic activation of Nrf2 results in much larger numbers of detoxication and lipid metabolism gene changes. Additionally, analysis of pharmacologic activation suggests that Nrf2 is the primary mediator of CDDO-Im activity, though other cell-signaling targets are also modulated following an oral dose of 30 μmol/kg.